NTLA

NASD Intellia Therapeutics, Inc.

Oct 26, 2026 · 11:14 PM ET EOD Market Closed

$11.26 ↑ +0.00 (+0.00%) Trading Up from the previous close of $11.26, $0.18 below the day’s high of $11.44

YTD change: +25.25%
vs 20-day SMA: -5.58%
vs 200-day SMA: -13.70%

Price ranges

Previous day

$10.58 $11.24

open $11.00 close $11.21

+$0.21 (+1.91%)

Today

$11.09 $11.44

open $11.24 now $11.26

+$0.02 (+0.18%)

Past week

$10.58 $12.00

from $11.42 now $11.26

-$0.16 (-1.40%)

Past month

$10.58 $13.27

from $11.75 now $11.26

-$0.49 (-4.17%)

This year

$8.99 $18.48

from $8.99 now $11.26

+$2.27 (+25.25%)

Price & Performance

-1.78 (-13.65%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good

The stock is 94.4% away from all-time highs of $202.73
NTLA is up 25% since the beginning of the year
NTLA is down 56% over the past 12 months
NTLA is down 4% over the past 1 month
34% of all NTLA investors are betting against NTLA

NTLA reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -23.9%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-0.8

Earnings momentum -0.4% Quarterly EPS growth

Quarterly change -0.4%

Valuation

P/E ratio N/A

Enterprise value $1.1B

Beta 2.46

Balance sheet & scale

IncomeN/A

Revenue$59.5M

Cash$437.8M

Debt$73.4K

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Professional, Scientific, and Technical Services

Industry Group Scientific Research and Development Services

Market cap $1.6B

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Competitor comparison

Ticker	Company	Price	Change
AMGN	Amgen Inc.	$444.63	+1.22%
MRNA	Moderna, Inc.	$198.85	-0.62%
RVMD	Revolution Medicines, Inc.	$183.90	-1.65%
ROIV	Roivant Sciences Ltd.	$36.05	-1.21%
BNTX	BioNTech SE Sponsored ADR	$86.86	-1.42%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.